Looking for first-in-class glory, Boehringer Ingelheim acquires two preclinical cancer drugs from Versant-backed biotech
Wading deeper into the next wave of immuno-oncology, Boehringer Ingelheim has bought up a Versant-launched preclinical pipeline focused on the tumor microenvironment.
The acquisition of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.